Top

Published in:

Open Access 01-12-2021 | Tamoxifen | Review

Tamoxifen and oxidative stress: an overlooked connection

Authors: Nermin S. Ahmed, Marek Samec, Alena Liskova, Peter Kubatka, Luciano Saso

Published in: Discover Oncology | Issue 1/2021

Abstract

Tamoxifen is the gold standard drug for the treatment of breast cancer in pre and post-menopausal women. Its journey from a failing contraceptive to a blockbuster is an example of pharmaceutical innovation challenges. Tamoxifen has a wide range of pharmacological activities; a drug that was initially thought to work via a simple Estrogen receptor (ER) mechanism was proven to mediate its activity through several non-ER mechanisms. Here in we review the previous literature describing ER and non-ER targets of tamoxifen, we highlighted the overlooked connection between tamoxifen, tamoxifen apoptotic effects and oxidative stress.

Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. Front Pharmacol. 2017;8:620. https://doi.org/10.3389/fphar.2017.00620.CrossRefPubMedPubMedCentral

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–36. https://doi.org/10.1001/jama.2009.1420.CrossRefPubMedPubMedCentral

Jordan VC. Selective estrogen receptor modulation. Cancer Cell. 2004;5:207–13. https://doi.org/10.1016/S1535-6108(04)00059-5.CrossRefPubMed

Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 1987;10:31–5. https://doi.org/10.1007/BF01806132.CrossRefPubMed

Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997;410:87–90. https://doi.org/10.1016/s0014-5793(97)00413-4.CrossRefPubMed

Smith CL, Nawaz Z, O’Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997;11:657–66. https://doi.org/10.1210/mend.11.6.0009.CrossRefPubMed

Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids. 2002;67:15–24. https://doi.org/10.1016/s0039-128x(01)00133-7.CrossRefPubMed

Metzger D, Ali S, Bornert JM, Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J Biol Chem. 1995;270:9535–42. https://doi.org/10.1074/jbc.270.16.9535.CrossRefPubMed

Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA. 1994;91:8517–21. https://doi.org/10.1073/pnas.91.18.8517.CrossRefPubMedPubMedCentral

10.

Benten WP, Stephan C, Lieberherr M, Wunderlich F. Estradiol signaling via sequestrable surface receptors. Endocrinology. 2001;142:1669–77. https://doi.org/10.1210/endo.142.4.8094.CrossRefPubMed

11.

Miller CP, Komm BS. Chapter 15. Targeting the estrogen receptor with SERMs. Elsevier; 2001. p. 149–58.

12.

Minutolo F, Bertini S, Papi C, Carlson KE, Katzenellenbogen JA, Macchia M. Salicylaldoxime moiety as a phenolic “A-Ring” substitute in estrogen receptor ligands. J Med Chem. 2001;44:4288–91. https://doi.org/10.1021/jm010948j.CrossRefPubMed

13.

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927–37. https://doi.org/10.1016/s0092-8674(00)81717-1.CrossRefPubMed

14.

Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–8. https://doi.org/10.1038/39645.CrossRefPubMed

15.

Jordan VC. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L Walpole. Breast Cancer Res Treat. 1988;11:197–209. https://doi.org/10.1007/BF01807278.CrossRefPubMed

16.

Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–5. https://doi.org/10.1038/bjc.1971.33.CrossRefPubMedPubMedCentral

17.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300. https://doi.org/10.1016/S0140-6736(03)12342-2.CrossRefPubMed

18.

Naugler C. Estrogen receptor testing and 10-year mortality from breast cancer: a model for determining testing strategy. J Pathol Inform. 2012;3:19. https://doi.org/10.4103/2153-3539.95452.CrossRefPubMedPubMedCentral

19.

Mouridsen HT, Rose C, Brincker H, Thorpe SM, Rank F, Fischerman K, et al. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group’s trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res. 1984;96:117–28. https://doi.org/10.1007/978-3-642-82357-2_14.CrossRefPubMed

20.

Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol. 1988;27:699–705. https://doi.org/10.3109/02841868809091772.CrossRefPubMed

21.

Rohlff C, Blagosklonny MV, Kyle E, Kesari A, Kim IY, Zelner DJ, et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1). Prostate. 1998;37:51–9. https://doi.org/10.1002/(sici)1097-0045(19980915)37:1%3c51::aid-pros8%3e3.0.co;2-b.CrossRefPubMed

22.

Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD, et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol. 1998;55:523–31. https://doi.org/10.1016/s0006-2952(97)00594-7.CrossRefPubMed

23.

Sharif TR, Sharif M. A novel approach for examining the anti-proliferative effect of protein kinase C inhibitors against human astrocytoma cells. Int J Oncol. 1998;13:685–92. https://doi.org/10.3892/ijo.13.4.685.CrossRefPubMed

24.

Lavie Y, Zhang ZC, Cao HT, Han TY, Jones RC, Liu YY, et al. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer. 1998;77:928–32. https://doi.org/10.1002/(sici)1097-0215(19980911)77:6%3c928::aid-ijc22%3e3.0.co;2-w.CrossRefPubMed

25.

Wang X-Y, Wang Y, Liu H-C. Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells. Biomed Pharmacother. 2011;65:525–8. https://doi.org/10.1016/j.biopha.2011.06.002.CrossRefPubMed

26.

Hoelting T, Siperstein AE, Duh QY, Clark OH. Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo. J Clin Endocrinol Metab. 1995;80:308–13. https://doi.org/10.1210/jcem.80.1.7829632.CrossRefPubMed

27.

Matsuoka H, Tsubaki M, Yamazoe Y, Ogaki M, Satou T, Itoh T, et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res. 2009;315:2022–32. https://doi.org/10.1016/j.yexcr.2009.04.009.CrossRefPubMed

28.

Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. 1997;57:3585–93.PubMed

29.

Tong S, Chen Q, Shan S-Q, Dewhirst MW, Yuan F. Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay. Angiogenesis. 2006;9:53–8. https://doi.org/10.1007/s10456-006-9029-x.CrossRefPubMed

30.

Cáceres W, González S. Angiogenesis and cancer: recent advances. P R Health Sci J. 2003;22:149–51.PubMed

31.

Davizon-Castillo P, Di Paola J. Tamoxifen suppresses platelet activation-supported angiogenesis and metastasis. Arterioscler Thromb Vasc Biol. 2017;37:611–2. https://doi.org/10.1161/ATVBAHA.117.309105.CrossRefPubMedPubMedCentral

32.

Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, McKinna A, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992;52:4261–4.PubMed

33.

McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN, Bouchier-Hayes DJ. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol. 2001;27:714–8. https://doi.org/10.1053/ejso.2001.1177.CrossRefPubMed

34.

Shen L-Z, Hua Y-B, Yu X-M, Xu Q, Chen T, Wang J-H, et al. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J Gastroenterol. 2005;11:1060–4. https://doi.org/10.3748/wjg.v11.i7.1060.CrossRefPubMedPubMedCentral

35.

Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, et al. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J Surg Res. 1996;66:31–5. https://doi.org/10.1006/jsre.1996.0368.CrossRefPubMed

36.

Liu Z-H, Ma Y-L, He Y-P, Zhang P, Zhou Y-K, Qin H. Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics. Mol Biol Rep. 2011;38:1769–75. https://doi.org/10.1007/s11033-010-0291-z.CrossRefPubMed

37.

Bogush EA, Ravcheeva AB, Bogush TA, Zabotina TN, Kadagidze ZG, Davydov MI. A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer. Dokl Biochem Biophys. 2007;413:83–7. https://doi.org/10.1134/s1607672907020123.CrossRefPubMed

38.

Bogush TA, Dudko EA, Beme AA, Bogush EA, Kim AI, Polotsky BE, et al. Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc). 2010;75:1421–7. https://doi.org/10.1134/s0006297910120011.CrossRef

39.

Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S, Davydov M. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev. 2012;6:e15. https://doi.org/10.4081/oncol.2012.e15.CrossRefPubMedPubMedCentral

40.

Chang M. Tamoxifen resistance in breast cancer. Biomol Ther (Seoul). 2012;20:256–67. https://doi.org/10.4062/biomolther.2012.20.3.256.CrossRef

41.

Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart M. Endocrine treatment in breast cancer: cure, resistance and beyond. Cancer Treat Rev. 2016;50:68–81. https://doi.org/10.1016/j.ctrv.2016.08.008.CrossRefPubMed

42.

Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13:513–29. https://doi.org/10.1200/JCO.1995.13.2.513.CrossRefPubMed

43.

Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH, Windschitl HE, et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer. 1991;68:34–9. https://doi.org/10.1002/1097-0142(19910701)68:1%3c34::aid-cncr2820680107%3e3.0.co;2-q.CrossRefPubMed

44.

Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386–95. https://doi.org/10.1200/JCO.2002.10.058.CrossRefPubMed

45.

Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–403. https://doi.org/10.1200/JCO.2002.10.057.CrossRefPubMed

46.

Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87:446–51. https://doi.org/10.1093/jnci/87.6.446.CrossRefPubMed

47.

Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994;54:349–53.PubMed

48.

Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat. 1994;31:129–38. https://doi.org/10.1007/BF00689683.CrossRefPubMed

49.

MacGregor Schafer J, Liu H, Bentrem DJ, Zapf JW, Jordan VC. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 2000;60:5097–105.PubMed

50.

Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000;60:4026–9.PubMed

51.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, et al. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013;73:6856–64. https://doi.org/10.1158/0008-5472.CAN-13-1197.CrossRefPubMed

52.

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12:573–83. https://doi.org/10.1038/nrclinonc.2015.117.CrossRefPubMedPubMedCentral

53.

Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22:16. https://doi.org/10.1186/s13058-020-1246-5.CrossRefPubMedPubMedCentral

54.

Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994;54:2552–5.PubMed

55.

de Celis JF, Barrio R. Regulation and function of Spalt proteins during animal development. Int J Dev Biol. 2009;53:1385–98. https://doi.org/10.1387/ijdb.072408jd.CrossRefPubMed

56.

Kelberman D, Islam L, Lakowski J, Bacchelli C, Chanudet E, Lescai F, et al. Mutation of SALL2 causes recessive ocular coloboma in humans and mice. Hum Mol Genet. 2014;23:2511–26. https://doi.org/10.1093/hmg/ddt643.CrossRefPubMedPubMedCentral

57.

Liu H, Adler AS, Segal E, Chang HY. A transcriptional program mediating entry into cellular quiescence. PLoS Genet. 2007;3:e91. https://doi.org/10.1371/journal.pgen.0030091.CrossRefPubMedPubMedCentral

58.

Ye L, Lin C, Wang X, Li Q, Li Y, Wang M, et al. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO Mol Med. 2019;11:e10638. https://doi.org/10.15252/emmm.201910638.CrossRefPubMedPubMedCentral

59.

Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55:471–8. https://doi.org/10.1007/s00280-004-0926-7.CrossRefPubMed

60.

Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997;57:3402–6.PubMed

61.

Brauch H, Schwab M. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol. 2014;77:695–703. https://doi.org/10.1111/bcp.12229.CrossRefPubMedPubMedCentral

62.

Ramón y Cajal T, Altés A, Paré L, del Rio E, Alonso C, Barnadas A, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat. 2010;119: 33–38. Doi: https://doi.org/10.1007/s10549-009-0328-y

63.

de Souza JA, Olopade OI. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol. 2011;38:263–73. https://doi.org/10.1053/j.seminoncol.2011.01.002.CrossRefPubMedPubMedCentral

64.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2013;31:176–80. https://doi.org/10.1200/JCO.2012.44.6625.CrossRefPubMed

65.

Gao L, Sun X, Tu Y, Ågren H, Eriksson LA. Modification of the anticancer drug tamoxifen to avoid CYP2D6 polymorphism. Can J Chem. 2013;91:916–24. https://doi.org/10.1139/cjc-2012-0537.CrossRef

66.

Elghazawy NH, Engel M, Hartmann RW, Hamed MM, Ahmed NS, Abadi AH. Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents. Future Med Chem. 2016;8:249–56. https://doi.org/10.4155/fmc.15.181.CrossRefPubMed

67.

Ahmed NS, Wober J. Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line. Drug Dev Res. 2020;81:444–55. https://doi.org/10.1002/ddr.21637.CrossRefPubMed

68.

Ahmed NS, Elghazawy NH, ElHady AK, Engel M, Hartmann RW, Abadi AH. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism. Eur J Med Chem. 2016;112:171–9. https://doi.org/10.1016/j.ejmech.2016.02.026.CrossRefPubMed

69.

Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73:1589–98. https://doi.org/10.1007/s00228-017-2323-2.CrossRefPubMedPubMedCentral

70.

Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 2007;9:R7. https://doi.org/10.1186/bcr1640.CrossRefPubMedPubMedCentral

71.

Charoenchokthavee W, Areepium N, Panomvana D, Sriuranpong V. Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients. BCTT. 2017;9:249–56. https://doi.org/10.2147/BCTT.S125745.CrossRef

72.

Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005;217:61–72. https://doi.org/10.1016/j.canlet.2004.08.027.CrossRefPubMed

73.

Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187–93. https://doi.org/10.1200/JCO.2007.12.2705.CrossRefPubMed

74.

Sanchez-Spitman AB, Swen JJ, Dezentjé VO, Moes DJAR, Gelderblom H, Guchelaar HJ. Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. Sci Rep. 2021;11:415. https://doi.org/10.1038/s41598-020-79972-x.CrossRefPubMedPubMedCentral

75.

Goetz MP, Sangkuhl K, Guchelaar H-J, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018;103:770–7. https://doi.org/10.1002/cpt.1007.CrossRefPubMed

76.

Mokbel K, Mokbel K. Does CYP2D6 Genotyping have a Role in Guiding Tamoxifen Therapy? Biochem Mol Biol J. 2017. https://doi.org/10.21767/2471-8084.100041.CrossRef

77.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007;96:2224–31. https://doi.org/10.1002/jps.20892.CrossRefPubMed

78.

Ahn S-J, Yoon M-S, Hyuk S, Han W, Yoon Y-D, Han J-S, et al. Phospholipase C-protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis. J Cell Biochem. 2003;89:520–8. https://doi.org/10.1002/jcb.10532.CrossRefPubMed

79.

Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 2003;63:8037–50.PubMed

80.

Li C, Zhou C, Wang S, Feng Y, Lin W, Lin S, et al. Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3β/β-catenin signaling pathway. PLoS ONE. 2011;6:e27053. https://doi.org/10.1371/journal.pone.0027053.CrossRefPubMedPubMedCentral

81.

Moodbidri MS, Shirsat NV. Activated JNK brings about accelerated apoptosis of Bcl-2-overexpressing C6 glioma cells on treatment with tamoxifen. J Neurochem. 2005;92:1–9. https://doi.org/10.1111/j.1471-4159.2004.02855.x.CrossRefPubMed

82.

Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, et al. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res. 1999;5:2971–7.PubMed

83.

Han P, Kang J-H, Li H-L, Hu S-X, Lian H-H, Qiu P-P, et al. Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. Biochem Biophys Res Commun. 2009;385:251–6. https://doi.org/10.1016/j.bbrc.2009.05.059.CrossRefPubMed

84.

Nagahara Y, Shiina I, Nakata K, Sasaki A, Miyamoto T, Ikekita M. Induction of mitochondria-involved apoptosis in estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B. Cancer Sci. 2008;99:608–14. https://doi.org/10.1111/j.1349-7006.2007.00709.x.CrossRefPubMed

85.

Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res. 2007;67:1282–90. https://doi.org/10.1158/0008-5472.CAN-06-3099.CrossRefPubMed

86.

Mandlekar S, Yu R, Tan TH, Kong AN. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 2000;60:5995–6000.PubMed

87.

Pawar P, Ma L, Byon CH, Liu H, Ahn E-Y, Jhala N, et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res. 2009;15:1288–96. https://doi.org/10.1158/1078-0432.CCR-08-1150.CrossRefPubMedPubMedCentral

88.

Zhao W-J, Wang K. NGX6 expression improves the sensitivity of tamoxifen-resistant MCF-7 cells through modulation of the Smad signaling pathway. Int J Oncol. 2013;42:2060–8. https://doi.org/10.3892/ijo.2013.1886.CrossRefPubMed

89.

Liu C-Y, Hung M-H, Wang D-S, Chu P-Y, Su J-C, Teng T-H, et al. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Res. 2014;16:431. https://doi.org/10.1186/s13058-014-0431-9.CrossRefPubMedPubMedCentral

90.

Li W, Shi X, Xu Y, Wan J, Wei S, Zhu R. Tamoxifen promotes apoptosis and inhibits invasion in estrogen-positive breast cancer MCF-7 cells. Mol Med Rep. 2017;16:478–84. https://doi.org/10.3892/mmr.2017.6603.CrossRefPubMed

91.

Rouhimoghadam M, Safarian S, Carroll JS, Sheibani N, Bidkhori G. Tamoxifen-induced apoptosis of MCF-7 cells via GPR30/PI3K/MAPKs interactions: verification by ODE modeling and RNA sequencing. Front Physiol. 2018;9:907. https://doi.org/10.3389/fphys.2018.00907.CrossRefPubMedPubMedCentral

92.

Ghasemi M, Malek M, Javanmard SH, Ghasemi A, Esfahani HN, Vaseghi G. Atorvastatin enhances apoptotic effects of tamoxifen on melanoma cancer cells. Bratisl Lek Listy. 2019;120:752–6. https://doi.org/10.4149/BLL_2019_125.CrossRefPubMed

93.

Sanaei M, Kavoosi F, Atashpour S, Haghighat S. Effects of genistein and synergistic action in combination with tamoxifen on the HepG2 human hepatocellular carcinoma cell line. Asian Pac J Cancer Prev. 2017;18:2381–5. https://doi.org/10.22034/APJCP.2017.18.9.2381.CrossRefPubMedPubMedCentral

94.

Motawi TK, Abdelazim SA, Darwish HA, Elbaz EM, Shouman SA. Modulation of tamoxifen cytotoxicity by caffeic acid phenethyl ester in MCF-7 breast cancer cells. Oxid Med Cell Longev. 2016;2016:3017108. https://doi.org/10.1155/2016/3017108.CrossRefPubMed

95.

Ganji-Harsini S, Khazaei M, Rashidi Z, Ghanbari A. Thymoquinone could increase the efficacy of tamoxifen induced apoptosis in human breast cancer cells: an in vitro study. Cell J. 2016;18:245–54. https://doi.org/10.22074/cellj.2016.4320.CrossRefPubMedPubMedCentral

96.

Rajput S, Kumar BNP, Sarkar S, Das S, Azab B, Santhekadur PK, et al. Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS ONE. 2013;8:e61342. https://doi.org/10.1371/journal.pone.0061342.CrossRefPubMedPubMedCentral

97.

Ghatreh Samani K, Farrokhi E, Tabatabaee A, Jalilian N, Jafari M. Synergistic effects of lauryl gallate and tamoxifen on human breast cancer cell. Iran J Public Health. 2020;49:1324–9. https://doi.org/10.18502/ijph.v49i7.3586.CrossRefPubMedPubMedCentral

98.

Abdallah ME, El-Readi MZ, Althubiti MA, Almaimani RA, Ismail AM, Idris S, et al. Tamoxifen and the PI3K inhibitor: LY294002 synergistically induce apoptosis and cell cycle arrest in breast cancer MCF-7 cells. Molecules. 2020. https://doi.org/10.3390/molecules25153355.CrossRefPubMedPubMedCentral

99.

Catanzaro E, Seghetti F, Calcabrini C, Rampa A, Gobbi S, Sestili P, et al. Identification of a new tamoxifen-xanthene hybrid as pro-apoptotic anticancer agent. Bioorg Chem. 2019;86:538–49. https://doi.org/10.1016/j.bioorg.2019.02.017.CrossRefPubMed

100.

Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453–62. https://doi.org/10.1016/j.cub.2014.03.034.CrossRefPubMedPubMedCentral

101.

Famurewa AC, Ekeleme-Egedigwe CA, David EE, Eleazu CO, Folawiyo AM, Obasi NA. Zinc abrogates anticancer drug tamoxifen-induced hepatotoxicity by suppressing redox imbalance, NO/iNOS/NF-ĸB signaling, and caspase-3-dependent apoptosis in female rats. Toxicol Mech Methods. 2020;30:115–23. https://doi.org/10.1080/15376516.2019.1669243.CrossRefPubMed

102.

Suddek GM. Protective role of thymoquinone against liver damage induced by tamoxifen in female rats. Can J Physiol Pharmacol. 2014;92:640–4. https://doi.org/10.1139/cjpp-2014-0148.CrossRefPubMed

103.

Adikwu E, Ebinyo NC, Benalayefa O. Protective effect of lycopene against tamoxifen-induced hepatotoxicity in albino rats. Biomed Biotechnol Res J (BBRJ). 2020;4(1):69.

104.

El-Shorbagy HM. Potential anti-genotoxic effect of sodium butyrate to modulate induction of DNA damage by tamoxifen citrate in rat bone marrow cells. Cytotechnology. 2017;69:89–102. https://doi.org/10.1007/s10616-016-0039-2.CrossRefPubMed

105.

Jena SK, Suresh S, Sangamwar AT. Modulation of tamoxifen-induced hepatotoxicity by tamoxifen-phospholipid complex. J Pharm Pharmacol. 2015;67:1198–206. https://doi.org/10.1111/jphp.12422.CrossRefPubMed

106.

Pandey SK, Ghosh S, Maiti P, Haldar C. Therapeutic efficacy and toxicity of tamoxifen loaded PLA nanoparticles for breast cancer. Int J Biol Macromol. 2015;72:309–19. https://doi.org/10.1016/j.ijbiomac.2014.08.012.CrossRefPubMed

107.

Javid S, Ziamajidi N, Foroughi S, Abbasalipourkabir R. Effects of tamoxifen-loaded solid lipid nanoparticles on the estrogen receptor-α (ER-α) and vascular endothelial growth factor-A (VEGF-A) genes expression in the endometrial tissue of ovariectomized female Sprague-Dawley rats. Int J Biol Macromol. 2017;96:706–12. https://doi.org/10.1016/j.ijbiomac.2016.12.055.CrossRefPubMed

108.

Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med. 2008;45:537–46. https://doi.org/10.1016/j.freeradbiomed.2008.05.011.CrossRefPubMed

109.

Bekele RT, Venkatraman G, Liu R-Z, Tang X, Mi S, Benesch MGK, et al. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance. Sci Rep. 2016;6:21164. https://doi.org/10.1038/srep21164.CrossRefPubMedPubMedCentral

110.

Perumal SS, Shanthi P, Sachdanandam P. Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria. Chem Biol Interact. 2005;152:49–58. https://doi.org/10.1016/j.cbi.2005.01.007.CrossRefPubMed

111.

Subramani T, Yeap SK, Ho WY, Ho CL, Omar AR, Aziz SA, et al. Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen. J Cell Mol Med. 2014;18:305–13. https://doi.org/10.1111/jcmm.12188.CrossRefPubMed

Title: Tamoxifen and oxidative stress: an overlooked connection
Authors: Nermin S. Ahmed
Marek Samec
Alena Liskova
Peter Kubatka
Luciano Saso
Publication date: 01-12-2021
Publisher: Springer US
Keywords: Tamoxifen
Breast Cancer
Breast Cancer
Selective Estrogen Receptor Modulator
Published in: Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-021-00411-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study

Selenite-induced ROS/AMPK/FoxO3a/GABARAPL-1 signaling pathway modulates autophagy that antagonize apoptosis in colorectal cancer cells

O-GlcNAcylation links oncogenic signals and cancer epigenetics

Welcome from the new Discover Oncology journal

Does circulating progesterone mediate the associations of single nucleotide polymorphisms in progesterone receptor (PGR)-related genes with mammographic breast density in premenopausal women?

Sphincter preservation in patients with low rectal cancer: striking the right oncological balance

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials